Donepezil

Evidence Level: L5

Predicted Indications: 8

Donepezil

Pharmacist Assessment Report

Donepezil: Acetylcholinesterase inhibitor → psychogenic movement disorders

One-Sentence Summary

Donepezil is a cholinesterase inhibitor marketed in Canada under many licences. The TxGNN model predicts it may be effective for psychogenic movement disorders, but no clinical trials and no publications currently support this specific prediction, so it remains a model-only signal.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Psychogenic movement disorders
TxGNN Prediction Score	0.9923
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs on record: at least 20)
Number of DINs	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for donepezil is not available in the data compiled for this report. Donepezil is generally known as an acetylcholinesterase inhibitor that raises cholinergic tone, and cholinergic signalling in the basal ganglia is involved in the control of movement.

That link is plausible but speculative for this condition. Psychogenic movement disorders are functional in origin, and no established pharmacological target for donepezil has been identified for them. The high model score is therefore not backed by any trial, case report or mechanistic study in the compiled data.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

The data compiled for this report show 20 valid single-ingredient licences, with no cancelled licences. The list may be partial. Dosage form and approved-indication text are not recorded in the local data.

DIN	Product Name	Dosage Form	Approved Indication
02232044	ARICEPT	Not recorded	Not recorded
02232043	ARICEPT	Not recorded	Not recorded
02362279	APO-DONEPEZIL	Not recorded	Not recorded
02328682	SANDOZ DONEPEZIL	Not recorded	Not recorded
02340615	TEVA-DONEPEZIL	Not recorded	Not recorded

Safety Considerations

Drug Interactions: 100 interactions were found in the interaction screening. The entries listed include:
- Major: Bupropion
- Moderate: Famotidine, Ranitidine, Cimetidine, Hyoscyamine, Atropine, Glycopyrronium, Clidinium, Dicyclomine, Dexamethasone, Metronidazole, Loperamide, Dolasetron, Picosulfuric acid
- Minor: Aprepitant, Acetylsalicylic acid, Lorcaserin, Clarithromycin
Many of the moderate entries are anticholinergic agents, which may oppose donepezil’s pharmacological action.

For warnings and contraindications, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high (0.9923), but no clinical trials or publications address psychogenic movement disorders. The mechanistic rationale is speculative, so the evidence level is L5.

To proceed, the following is needed:

Any direct clinical or preclinical evidence in psychogenic (functional) movement disorders
Detailed mechanism-of-action data for donepezil
Package insert warnings and contraindications from Health Canada
A safety review, since the interaction screening flagged a major interaction (bupropion) and several anticholinergic combinations, and the literature on cholinesterase inhibitors reports movement-disorder adverse effects in some patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.